The World Market for Prescription Arthritis Treatments (NSAIDs, DMARDs, BRMs and Immunosuppressants)
|出版日||ページ情報||英文 150 Pages
|世界の関節炎処方薬市場 The World Market for Prescription Arthritis Treatments (NSAIDs, DMARDs, BRMs and Immunosuppressants)|
|出版日: 2011年11月01日||ページ情報: 英文 150 Pages||
Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid arthritis, which is an autoimmune disease. Successful treatment of arthritis has resulted from a growing array of therapies available to physicians.
While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management. This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides market sizes and forecasts for the following categories of treatments:
For each category, the report breaks down the regional market (US, Europe, Japan, Rest of World), lists major products, and provides market share among major competitors.
There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include:
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the worldwide arthritis treatment market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 20 industry executives and product managers to validate and obtain expert opinion on current and future trends in the worldwide prescription arthritis treatment market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
The following companies are profiled in the report:
All market data pertains to the worldwide market at the manufacturers' level. Data are expressed in current U.S. dollars. A geographic breakdown is also included for US, Europe, Japan and Rest of World total market and in each drug type segment. The base year for data was 2011. Historical data are provided for each of the years 2009 to 2011, and forecast data are provided for each of the years 2011 through 2016. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2011 base year.
All Kalorama Information reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
New York, December 5 , 2011-- Led by biologic therapies, the market for prescription arthritis treatments will exceed $20 billion in 2011, according to Kalorama Information. The healthcare market research publisher says that drugs that attack Tumor Necrosis Factor (TNF) led the market to 7.3% growth in revenues in 2010, and this type of growth is expected to continue, but not without challenges.
TNF is a type of cell death that leads to inflammation and is a main cause of arthritis pain. According to the report, products such as Remicade, Enbrel or Humira that can block TNF have been effective treatments and are leading in terms of revenue for the treatment of rheumatoid arthritis. Abbott's Humira leads the group of TNF products, but as the report's author suggests, the success of these products with rheumatologists and patients also means that it has become a competitive marketplace.
"Humira will likely become the world's biggest-selling drug by 2016, after the fall of Lipitor in 2011," said Melissa Elder, the report's author. "However, new products on the horizon and other factors may challenge this dominance over the next five years."
Entrants to this area include Bristol-Myers Squibb, with its recent introduction of Orencia, UCB with Cimzia and many others; so far the existing products have fended off those challenges. According to the report, some of the key factors that may challenge the dominance of treatments that attack TNF include new small molecule therapies that are attempting to vie for first-line utilization, the launch of biosimilars and physicians gaining comfort with IL-6 therapies; one or all of these could potentially derail the anti-TNF dominance.
The report notes that the prescription arthritis market is not without its challenges for all drug makers. Reimbursement for high-priced biologic medicines will be challenging over the next few years as payers seek to manage costs through purchasing arrangements and cost-sharing with their insured population, which could be a limiter to price growth, according to the report.